OpenAlex
PricingAboutJobs
Log inGet started
Work

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

HTML

Year: 2010
Type: article
Study design: Clinical Trial
Source: Clinical Cancer Research
DOI: 10.1158/1078-0432.ccr-09-1920
Authors: Eric B. Haura, Alejandro D. Ricart, Timothy G. Larson, Philip J. Stella, Lyudmila Bazhenova, Vincent A. Miller, Roger B. Cohen, Peter D. Eisenberg, Paulina Selaru, Keith D. Wilner, Shirish M. Gadgeel
Institutions: Fox Chase Cancer Center, Moffitt Cancer Center, University of California San Diego, Trinity Health Ann Arbor Hospital, North Memorial Health Care, Pfizer (United States)
Language: English

Topic: Lung Cancer Treatments and Mutations
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: PD0325901, MEK inhibitors, non-small cell lung cancer, advanced non-small cell lung cancer, refractory disease, intermittent dosing, oral kinase inhibitor, EGFR inhibitors, drug toxicity, progression-free survival, objective response, pharmacokinetics, visual disturbances
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2120203403
FWCI: 20.17
Cites: 28
Cited by: 256
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security